University of Manchester to Conduct Health Economic Study

20-Jul-2016 A team of pathology and health economics experts at the Manchester Molecular Pathology Innovation Centre at the University of Manchester (MMPathIC), UK, have begun work on an important study to define and quantify the health economic benefits of introducing Sienna’s IVD test for telomerase to the NHS across the United Kingdom.

The study will model the anticipated cost savings to the health system as a result of decreased “lifetime cost of care” generated from the use of a novel, cost-effective test that provides useful clinical information to aid in the diagnosis of bladder cancer when used as an adjunct to routine urine cytology testing.


No Very

Captcha Image

Sign up for updates